Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-05
2011-04-05
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07919515
ABSTRACT:
The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R, to R8each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.
REFERENCES:
patent: 5296486 (1994-03-01), Lazer et al.
patent: 6838453 (2005-01-01), Demassey et al.
patent: 2006/0160868 (2006-07-01), Majka et al.
patent: 2006/0160870 (2006-07-01), Majka et al.
patent: 2007/0088061 (2007-04-01), Majka et al.
patent: 1184366 (2002-03-01), None
patent: 58125039 (1983-07-01), None
patent: WO-95/25107 (1995-09-01), None
patent: 97/31907 (1997-09-01), None
patent: 01/17994 (2001-03-01), None
patent: 01-85729 (2001-11-01), None
patent: 03/011814 (2003-02-01), None
patent: 03/011834 (2003-02-01), None
Takano et al., Circulation Journal, vol. 73, Feb. 2009, pp. 214-220.
Auwerx, American Journal of Physiology, Gastrointestinal and Liver Physiology, Apr. 2002, 282(4), pp. G581-G585.
Colagiuri et al., American Journal of Public Health, Sep. 2006, vol. 96, No. 9, pp. 1562-1569.
Bruno et al., Expert Opinion Emerging Drugs, (2005), 10(4), pp. 747-771.
Park, Diabetes Research and Clinical Practice 66S (2004), S33-S35.
Curtis et al., The Journal of the American Board of Family Practice, vol. 18, pp. 37-43, (2005).
J. L. Collins et al., “N-(2-Benzoylphenyl)- L-Tyrosine PPARgamma Agonists. 2. Structure-Activity Relationship and Optimization of the PhenylAlkyl Ether Moiety,”, J. Med. Chem. vol. 41, pp. 5037-5054, (1998). XP-002211273.
J. E. Cobb et al., “N-(2-Benzoylphenyl)-L-Tyrosine PPARgamma Agonists. 2. Structure-Activity Relationship and Optimization of the N-Aryl Substituent”, J. Med. Chem. vol. 41, pp. 5055-5069 (1998). XP-002156427.
Lazer et al., Journal of Medicinal Chemistry, 37(7), pp. 913-923 (1994).
J. Rudolph, “Facile Access to N-Thiazolyl Alpha-Amino Acids From Alpha-Bromo Ketone and Alpha-Amino Acids”, Tetrahedron, vol. 56m 3161-3165 (2000).
Kurowski Krzysztof
Majka Zbigniew
Matusiewicz Katarzyna Joanna
Rusin Katarzyna Ewa
Sawicki Andrzej Wojciech
Adamed Sp. z o.o.
Fish & Richardson P.C.
Stockton Laura L.
LandOfFree
3-phenylpropionic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-phenylpropionic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-phenylpropionic acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668646